European Companies Search Engine
Capital: €25,000 · Shareholder agreement · Name · Proxy policy · Corporate Purpose Hrb12 Mar 2019 German Trade Register Announcements, Germany (27/02/2019)
Overview
Text
HRB 29861 P: Bramlage Capital UG (limited liability), Blankenfelde-
Unnamed street ??, 15831 Blankenfelde-Mahlow, Germany
. The name of the company is changed to: Bramlage Lifesciences GmbH; The aim is to manage own assets, in particular participation in other companies engaged in life sciences, and all related activities. Capital: EUR 25,000.00; Representation regulation: If a managing director is appointed, he shall represent the company alone. If several directors have been appointed, the company is represented jointly by two directors or by a managing director in community with one authorized representative. The power of sole representation may be granted. Board of Management: Change to No. 1: Managing Director: Dr. Bramlage, Peter; with the power to represent the company alone with the power to conduct legal transactions with itself or as a representative of third parties; Legal form: By resolution of the shareholders' meeting of January 31, 2019, the share capital is increased by EUR 24,000 to EUR 25,000.00 and the СД agreement is recast, in particular amended in Sections 1 (Company), Section 2 (Object), Section 3 (Capital) and Section 4 (Managing Director and Representation)
This filing was translated from German to English. The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Bramlage Lifesciences GmbH, Cloppenburg, Germany.
